Given the results from the cytotoxicity assay and tumor xenograft model that showed the capacity of CDK5 to promote chemosensitivity, we investigated the clinical value of CDK5 in gastric cancer. Using western blotting, we examined CDK5 protein levels in frozen gastric tumor tissues collected from 19 patients who received neoadjuvant chemotherapy (Additional file 2: Table
S2). The results showed that CDK5 protein expression was significantly higher in patients who developed chemoresistance than in those with sensitivity (Fig.
6A, p < 0.05). In addition, we tested CDK5 expression using IHC staining in TMAs with 340 evaluable gastric cancer tissues and 97 evaluable adjacent nontumor tissues (Additional file 1: Table
S1). Representative IHC staining for CDK5 low and high expression is shown in Fig.
6B. The histogram shows low CDK5 expression in 62.6% (213/340) of the tumor samples, which is remarkably higher than that in adjacent nontumor samples (22.7%, 22/97,
p < 0.001; Fig.
6B). Kaplan–Meier survival analysis indicated a worse OS rate in the CDK5-low group (hazard ratio [HR] = 0.72, 95% confidence interval [CI]: 0.53–0.97,
p = 0.03) than in the CDK5-high group (Fig.
6C). Similar results were obtained from analyses of the TCGA, ACRG, and GSE26942 cohorts (Fig.
6C;
p < 0.05). More importantly, we assessed the survival benefit in our cohort of 304 patients with available information on platinum- and fluorouracil-based ACT (Additional file 1: Table
S1). Our data demonstrated a significant survival benefit in the CDK5-high group who received ACT (HR = 0.36, 95% CI: 0.20–0.64,
p < 0.001) compared to the CDK5-low group (HR = 0.86, 95% CI: 0.59–1.20,
p = 0.419; Fig.
6D). This was further confirmed by adjusting for other clinicopathological features, including age, sex, tumor location, tumor size, and American Joint Committee on Cancer (AJCC) stage, in the Cox regression model (Fig.
6E). In summary, these results indicate that CDK5 depletion predicts poor survival and chemoresistance in patients with gastric cancer.